Welcome to our dedicated page for Atrium Therapeutics SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avidity Biosciences, Inc. (Nasdaq: RNA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into how Avidity describes its Antibody Oligonucleotide Conjugates (AOCs™) platform, its late-stage neuromuscular programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), and its broader pipeline in precision cardiology and immunology.
Current reports on Form 8-K are especially important for tracking material events at Avidity. Recent 8-K filings have covered topics such as the definitive merger agreement with Novartis AG, the related Separation and Distribution Agreement for the spin-off or sale of early-stage precision cardiology programs into SpinCo, positive clinical data from the EXPLORE44® and EXPLORE44-OLE™ trials of delpacibart zotadirsen (del-zota) in DMD44, and regulatory milestones including Breakthrough Therapy designation and updated BLA submission timing for del-zota. Other 8-Ks detail public equity offerings, amendments to equity incentive plans, and executive compensation arrangements in connection with the proposed merger.
Investors and analysts can also use Avidity’s SEC filings to confirm listing information for its common stock (trading under the symbol RNA on The Nasdaq Global Market), review descriptions of SpinCo and the planned spin-off structure, and understand the conditions, termination provisions and timing expectations associated with the Novartis transaction. These filings often reference additional documents such as proxy statements, registration statements for SpinCo and financial reports that further explain Avidity’s operations, risk factors and capital structure.
On Stock Titan, Avidity’s filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as clinical program updates, collaboration milestones, merger terms and changes in executive compensation. Real-time updates from EDGAR, combined with structured access to Forms 8-K and other filings, make this page a practical starting point for reviewing Avidity’s regulatory history, including material events related to its AOC platform, neuromuscular pipeline and the proposed acquisition by Novartis.
Avidity Biosciences director Noreen Henig reported multiple dispositions of stock options and common stock of Avidity Biosciences. The securities were surrendered to the company in connection with a planned merger under an Agreement and Plan of Merger with Novartis AG. According to the filing, the reported options were canceled under the merger terms in exchange for cash equal to the excess of the merger consideration of $72.00 over each option’s exercise price, leaving no remaining holdings from these awards.
Avidity Biosciences director Jean Jinsun Kim reported the disposition of stock options and common shares to the company in connection with its merger with Novartis. The filing shows multiple stock option awards and common stock, including shares from previously reported restricted stock units, were surrendered as part of the transaction.
According to the merger agreement among Novartis AG, Ajax Acquisition Sub, Inc., and Avidity Biosciences, the reported options were exchanged for cash equal to the merger consideration of $72.00 per share minus the applicable exercise price, rather than being sold in the open market.
Avidity Biosciences director Arthur A. Levin reported the cash-out of his equity in connection with the company’s merger with Novartis AG. On February 27, 2026, multiple stock options and shares of common stock were disposed of to the issuer under an Agreement and Plan of Merger dated October 25, 2025.
The filing shows dispositions of stock options and common stock, including 16,562 shares of common stock held directly and 131,372 shares held indirectly by a family trust. The footnotes state that options were cancelled in exchange for cash equal to the excess of the $72.00 per-share merger consideration over their exercise prices, and that common stock (including shares issuable from previously reported restricted stock units) was disposed of pursuant to the merger terms.
Avidity Biosciences director Edward M. Kaye, MD reported multiple dispositions of stock options and common shares to the company in connection with its acquisition by Novartis. The filing shows stock options and common stock were transferred to the issuer under a merger agreement with Novartis and Ajax Acquisition Sub.
According to the footnotes, the common shares (including those underlying previously reported restricted stock units) were disposed of pursuant to the Agreement and Plan of Merger dated October 25, 2025. The reported stock options were cashed out for a payment equal to the excess of the merger consideration of $72.00 per share over their exercise prices.
Avidity Biosciences director Carsten Boess reported dispositions of stock options and common shares in connection with the company’s acquisition by Novartis. Several “Stock Option (Right to Buy)” awards and 6,692 shares of common stock were transferred to the issuer under the merger agreement.
The options were canceled in exchange for a cash payment equal to the excess of the merger consideration of $72.00 per share over each option’s exercise price, reflecting cash-out treatment rather than open-market sales.
Avidity Biosciences Chief Commercial Officer Eric Mosbrooker reported the disposition of stock options and common shares in connection with the company’s merger with Novartis. The filing shows 177,188 and 50,000 stock options and 79,413 shares of common stock were transferred to the issuer.
According to the merger agreement dated October 25, 2025, the common stock, including shares underlying previously reported restricted stock units, was disposed of as part of the transaction. The options were cashed out for a payment equal to the excess of the merger consideration of $72.00 over each option’s exercise price.
Avidity Biosciences, Inc. Chief Technical Officer Charles Calderaro III reported disposing of company equity in connection with the planned acquisition by Novartis AG. He surrendered 98,547 shares of Common Stock (including shares underlying previously reported restricted stock units) and 80,000 stock options to the issuer pursuant to a Merger Agreement dated October 25, 2025. The options were cashed out for the excess of the merger consideration of $72.00 per share over their exercise price, reflecting merger-related settlement rather than open-market trading.
Avidity Biosciences, Inc. notified the removal/withdrawal of its Common Stock from listing and registration on the Nasdaq Stock Market LLC.
The notice states Nasdaq and the issuer each complied with the applicable rules under 17 CFR 240.12d2-2 governing voluntary withdrawal and removal procedures.